Form 4: ADC Therapeutics CLO Sells Shares for Tax Obligations
Insider Transaction Report
ADC Therapeutics' Chief Legal Officer, Peter J. Graham, disposed of 49,508 common shares to cover tax withholding obligations related to vested restricted share units.
Summary
- Peter J. Graham, Chief Legal Officer of ADC Therapeutics SA, reported a transaction on December 6, 2025.
- He disposed of 49,508 common shares at a price of $3.29 per share.
- This disposition was made to satisfy tax withholding obligations associated with the vesting of previously granted restricted share units.
- Following this transaction, Mr. Graham beneficially owns 359,034 common shares directly.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction for tax purposes, which is neither inherently positive nor negative for the company's operational or financial outlook.
Future Outlook
No forward-looking statements or guidance are provided in this insider transaction report.
Industry Context
This is a routine insider transaction related to executive compensation and does not provide specific insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: The transaction represents a minor, routine disposition of shares by an executive, which is a standard part of equity compensation plans and does not typically have a significant impact on overall shareholder value.
- Employees: The vesting of restricted share units, which led to this tax-related disposition, indicates the fulfillment of equity compensation, potentially reinforcing employee retention and alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 12/06/2025 | Date of transaction (disposition of common shares). |
| 12/09/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Recommendation
holdThe Form 4 details a routine disposition of shares by an executive to cover tax obligations related to vested equity awards. This type of transaction is common and does not typically reflect a change in the executive's confidence in the company or its future prospects, nor does it provide new material information about the company's operations or financial health. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
ADC Therapeutics, ADCT, Peter Graham, Chief Legal Officer, Form 4, insider transaction, share disposition, tax withholding, restricted share units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.